vbl
presents
human
data
show
potential
novel
monoclonal
antibodies
multiple
sclerosis
ms
virtual
meeting
tel
aviv
israel
globe
newswire
vbl
therapeutics
nasdaq
vblt
today
presents
first
time
new
data
demonstrating
activity
proprietary
investigational
mabs
patients
progressive
multiple
sclerosis
ms
vbl
study
presented
ms
virtual
virtual
joint
meeting
data
show
vbl
mabs
significantly
inhibited
migration
monocytes
isolated
ms
patients
included
study
regardless
disease
severity
gender
active
treatment
notably
activity
seen
monocytes
also
primary
progressive
secondary
progressive
patients
high
expanded
disability
status
scale
edss
scores
believe
antibodies
open
completely
novel
mechanism
potential
treatment
ms
blocking
accumulation
monocytes
macrophages
central
nervous
system
said
itzhak
mendel
immunology
director
vbl
therapeutics
mechanism
differentiated
existing
available
treatments
mostly
target
b
cells
therefore
surprising
antibodies
showed
activity
top
patient
active
therapy
backed
strong
preclinical
results
first
data
reinforce
therapeutic
potential
vbl
currently
advancing
lead
candidate
studies
aiming
start
study
link
vbl
presentation
ms
virtual
conference
see
link
vbl
platform
vbl
conducting
two
parallel
drug
development
programs
exploring
potential
motile
sperm
protein
protein
vbl
identified
key
regulator
cell
motility
therapeutic
target
inflammatory
diseases
cancer
platform
comprises
classical
monoclonal
antibodies
inflammatory
indications
well
antibody
candidates
oncology
vbl
vascular
biogenics
operating
vbl
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovery
development
commercialization
treatments
areas
unmet
need
cancer
immune
inflammatory
indications
vbl
developed
three
platform
technologies
based
technology
targeting
newly
formed
blood
vessels
focus
cancer
technology
targeting
applications
lecinoxoids
family
indications
vbl
lead
oncology
product
candidate
ofranergene
obadenovec
targeted
agent
developed
treat
wide
range
solid
tumors
conveniently
administered
iv
infusion
every
weeks
observed
cancer
patients
demonstrated
activity
signals
comers
phase
trial
well
three
phase
studies
ofranergene
obadenovec
currently
studied
phase
potential
registration
trial
ovarian
cancer
forward
looking
statements
press
release
contains
statements
statements
statements
historical
fact
statements
often
indicated
terms
anticipate
believe
could
estimate
expect
goal
intend
look
forward
may
plan
potential
predict
project
would
similar
expressions
statements
may
include
limited
statements
regarding
programs
including
including
clinical
development
therapeutic
potential
clinical
results
statements
promises
guarantees
involve
substantial
risks
uncertainties
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
uncertainties
associated
generally
research
development
clinical
trials
related
regulatory
reviews
approvals
risk
historical
clinical
trial
results
may
predictive
future
trial
results
impact
pandemic
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
clinical
results
financial
resources
last
long
anticipated
may
realize
expected
benefits
intellectual
property
protection
list
description
risks
uncertainties
risks
found
regulatory
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
filings
sec
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
vbl
therapeutics
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
investor
contact
michael
rice
lifesci
advisors
llc
